ADCs are designed to deliver chemotherapy directly to tumours. However, more than 95% of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity.
One of the things that makes patient engagement for pharma companies so challenging is that it's not something that can be added to one step of a process and then checked off the list.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.